首页> 外文OA文献 >Development of a Melting Tablet Containing Promethazine HCl Against Motion Sickness
【2h】

Development of a Melting Tablet Containing Promethazine HCl Against Motion Sickness

机译:含盐酸异丙嗪的抗晕动感溶片的研制

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The purpose of this study was to design a ‘Traveller Friendly Drug Delivery System’ for PM-HCl. Conventional promethazine (PM-HCl) tablets are bitter, need to be taken 1 h before symptoms and water is also needed. Taste-masked granules were produced with Eudragit® E100 by extrusion, and analyzed with FTIR, DSC, and XRD. Tablets formulated from granules by direct compression using Ac-Di-Sol, Polyplasdone®-XL, Primojel® and ion-exchanger Tulsion®339 and evaluated for mass uniformity, friability, tensile strength, drug content uniformity, water absorption ratio, in-vitro and in-vivo disintegration time and in-vitro dissolution studies. The observed drug-polymer interactions and reduced crystallinity may be reasons for increased dissolution rates. The formulated tablets were disintegrated within 15 s. Tablets (25 mg PM-HCl) with Ac-Di-Sol (4%) showed complete release within 1 min, while marketed conventional tablets (Phenergan®; Rhone-Poulec) release 25% during the same period. A preliminary stability studies for the prepared tablets carried at 30 ± 2°C/60 ± 5% RH, and 40 ± 2°C/75 ± 5%RH for 3 months showed no significant changes in the tablets quality at 30 ± 2°C/60 ± 5% RH. However, at 40 ± 2°C/75 ± 5%RH marked increase in in-vitro disintegration time, tensile strength and decrease in friability and water absorption ratio was found. The present studies indicate the abilities of Eudragit® E 100 for taste masking and improving the dissolution profile of PM-HCl after complexation. In addition, by employing cost effective direct compression method, fast-dissolving tablets of 400 mg total weight with an acceptable quality could be prepared.
机译:这项研究的目的是设计用于PM-HCl的“旅行者友好型药物输送系统”。常规异丙嗪(PM-HCl)片剂很苦,需要1小时服用才能出现症状和水。带有掩味的颗粒通过E100通过挤出生产,并用FTIR,DSC和XRD分析。使用Ac-Di-Sol,Polyplasdone®-XL,Primojel®和离子交换剂Tulsion®339通过直接压片从颗粒中制成的片剂,并进行了质量均匀性,易碎性,拉伸强度,药物含量均匀性,吸水率,体外的评估以及体内崩解时间和体外溶出度研究。观察到的药物-聚合物相互作用和结晶度降低可能是溶解速率增加的原因。配制的片剂在15秒内崩解。含Ac-Di-Sol(4%)的片剂(25 mg PM-HCl)在1分钟内显示完全释放,而市售的常规片剂(Phenergan®; Rhone-Poulec)在同一时期释放25%。制备的片剂在30°±2°C / 60°±5%RH和40°±2°C / 75°±5%RH的条件下进行3个月的初步稳定性研究表明,在30°±2°C的片剂质量没有明显变化C / 60±±5%RH。然而,在40±2℃/ 75±5%RH下,体外崩解时间明显增加,拉伸强度和脆性和吸水率降低。本研究表明,Eudragit®E 100具有掩盖味道和改善络合后PM-HCl溶出度的能力。此外,通过采用具有成本效益的直接压片方法,可以制备总质量为400 mg且质量合格的速溶片剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号